Oral News and Research

RSS

Young docs not so keen on immunizations: Survey

A cross-sectional survey of 551 healthcare providers and noted that more recent graduates were less likely to think that vaccines were efficacious said Saad Omer, assistant professor of Emory University in Atlanta. They were also more likely to have doubts about the safety of some vaccines, Omer told reporters at the 49th annual meeting of the Infectious Diseases Society of America (IDSA).

20 Oct 2011

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Intestinal ecosystem more dynamic than previously thought

The intestinal ecosystem is even more dynamic than previously thought, according to two studies by UT Southwestern Medical Center researchers published in the latest issue of Science.

20 Oct 2011

Tenofovir gel shows promise against HSV infection

HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.

20 Oct 2011

Haiti has highest rate of cholera worldwide one year after disease outbreak began

Paul Farmer, a founder of Partners in Health (PIH) and U.N. deputy special envoy to Haiti, in an interview with the Associated Press/Washington Post "said cholera has sickened more than 450,000 people in a nation of 10 million, or nearly five percent of the population, and killed more than 6,000," giving the Caribbean nation "the highest rate of cholera in the world a mere year after the disease first arrived."

20 Oct 2011

Famy Care, Mylan resolve Femcon Fe Chewable Tablets litigation with Warner Chilcott

Mylan Inc. today announced that it, along with Famy Care Ltd., has entered into a settlement agreement with Warner Chilcott resolving litigation related to Femcon Fe Chewable Tablets, known generically as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets USP (Chewable), 75 mg (28-Day Regimen).

19 Oct 2011

Oral laquinimod shows promise against multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability progression and brain volume loss.

19 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

FDA clears Cook Medical's Evolution Duodenal Controlled-Release Stent

Cook Medical announced today that its Evolution Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration.

18 Oct 2011

AHRQ: Asthma drug usage among children doubles

The proportion of children who used a prescribed controller drug to treat their asthma doubled from 29 percent in 1997-1998 to 58 percent in 2007-2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

18 Oct 2011

FDA clears BioHelix IsoAmp HSV molecular diagnostic assay

BioHelix Corporation has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company's first molecular diagnostic assay, the IsoAmp HSV Assay. The diagnostic test is intended for the detection of Herpes Simplex Virus (HSV1 & HSV2) in genital and oral lesion specimens from symptomatic patients.

18 Oct 2011

First-time mothers, obese women, and women who have longer labors are at higher risk for pain

According to a study presented at ANESTHESIOLOGY 2011 in Chicago, first-time mothers, obese women, and women who have longer labors are at higher risk for pain than other laboring women. Such information could be crucial in helping anesthesiologists determine how best to provide pain care with epidurals and other methods.

18 Oct 2011

Tailored postoperative treatment plan for women at high risk for severe pain after cesarean delivery

Nearly one third of children in the U.S. are born by cesarean delivery, a surgery that puts women at risk for persistent pain and postpartum depression. A new study presented at ANESTHESIOLOGY 2011 investigated whether an increase in pain treatment in patients at high risk for severe pain after surgery reduces these complications after a cesarean delivery.

18 Oct 2011

Brain tumour discovery offers drug treatment hope

Australian scientists have played a key role in the identification of a new biochemical mechanism that allows brain tumours to survive and grow, offering hope of new drug treatments for some of the most aggressive tumours.

17 Oct 2011

Myths and misconceptions about diabetes

November is designated American Diabetes Month and while raising awareness this month about preventing diabetes is important, focusing on proper treatment is just as important for those living with the disease.

15 Oct 2011

ABI provides clinical update on company activities

Amarillo Biosciences, Inc. (ABI) today provided an update on company activities.

15 Oct 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

Survey analyses management of patients suffering from EGFRI toxicities

A recent survey of nurses from seven European countries, published in the peer-reviewed journal ecancermedicalscience, has analysed the management of patients suffering from toxicities due to treatment with epidermal growth factor receptor inhibitors.

14 Oct 2011

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.

14 Oct 2011

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

A clinical trial to test better treatment options for chronic heroin addiction is expected to begin in Vancouver at the end of this year. Led by researchers from Providence Health Care and the University of British Columbia, it's the only clinical trial of its kind in North America.

13 Oct 2011